Show simple item record

dc.contributor.authorShinn, Richard L.en
dc.contributor.authorKani, Yukitakaen
dc.contributor.authorHsu, Fang-Chien
dc.contributor.authorRossmeisl, John H. Jr.en
dc.description.abstractBackground Stereotactic brain biopsy (SBB) allows for histopathologic diagnosis of brain tumors. Adverse events (AE) occur in 5 to 29% of dogs after SBB, but risk factors associated with developing AE are poorly described. Objective Identify clinicopathologic, diagnostic imaging, or procedural variables that are associated with AE in dogs after SBB. Animals Twenty-nine dogs with brain tumors. Methods Retrospective, case-control study. Dogs had laboratory investigations performed before SBB, as well as clinical examinations and diagnostic imaging of the brain before and after SBB. Cases experienced AE after SBB including transient exacerbation of preexisting neurologic deficits, transient new deficits, or permanent neurologic deficits. Controls had SBB performed without AE. Fisher's exact and Student'sttests were used to examine associations between the postulated risk factors and AE. Results Adverse events occurred in 8/29 (27%) dogs, and 7/8 AE (88%) were transient. Cases were significantly more likely to have T2W-heterogenous tumors (88 versus 38%;P= .04) and lower platelet counts (194.75 +/- 108.32 versus 284.29 +/- 68.54 x10(3)/mm(3),P= .006). Dogs with gradient echo signal voids present on baseline imaging were significantly more likely to have hemorrhage present after biopsy, and 7/8 (88%) of cases had hemorrhage on imaging after SBB. Conclusion and Clinical Importance Twenty-seven percent of dogs undergoing SBB experience AE, with the majority of AE resolving with 1 week. Platelet counts should be >= 185 000/mm(3)to minimize risk of SBB-associated AE. Observation of intracranial hemorrhage after biopsy can have important clinical implications, as this was observed in 88% of dogs with AE.en
dc.description.sponsorshipAmerican College of Veterinary Internal Medicine; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01CA207206, R01CA139099, R01CA213423]; ACVIM Advanced Clinical Training Fellowshipen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.subjectbrain tumoren
dc.subjectdiagnostic methodsen
dc.subjectrisk factorsen
dc.titleRisk factors for adverse events occurring after recovery from stereotactic brain biopsy in dogs with primary intracranial neoplasiaen
dc.typeArticle - Refereeden
dc.contributor.departmentSmall Animal Clinical Sciencesen
dc.description.notesAmerican College of Veterinary Internal Medicine, Grant/Award Number: ACVIM Advanced Clinical Training Fellowship; National Cancer Institute, Grant/Award Numbers: P01CA207206, R01CA139099, R01CA213423en
dc.title.serialJournal of Veterinary Internal Medicineen

Files in this item


This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution 4.0 International
License: Creative Commons Attribution 4.0 International